ASHLEY FOREMAN: Open Payments
NPI 1457776684 · HAMPTON, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,739 in 152 payments from 22 companies in 2025. Trend: 2023 $3,617 · 2024 $6,956 · 2025 $3,739
Food & beverage: $3,739
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 27 | $705 |
| AstraZeneca Pharmaceuticals LP | 16 | $701 |
| GENZYME CORPORATION | 9 | $330 |
| Amgen Inc. | 15 | $294 |
| Regeneron Healthcare Solutions, Inc. | 14 | $235 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $190 |
| Electromed, Inc. | 14 | $189 |
| Grifols USA, LLC | 6 | $185 |
| Verona Pharma, Inc. | 8 | $156 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $115 |
Products named: DUPIXENT, NUCALA, AIRSUPRA, TEZSPIRE, TRELEGY ELLIPTA, SMARTVEST, GLASSIA, Prolastin-C Liquid.
Industry payments across VA — which companies pay providers there.
